Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Philip D. Hansten, PharmD

Articles by Philip D. Hansten, PharmD

Inhaled Corticosteroids: Watch for Drug Interactions

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

September 1st 2004

Drug Interaction Classification Systems

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

August 1st 2004

Do NSAIDs Impair the Cardioprotective Effects of Aspirin?

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

July 1st 2004

Enhanced Warfarin Response and Antibiotics

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

June 1st 2004

St. John's Wort Interactions: What's New?

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

May 1st 2004

Oral Hypoglycemic Agents: The Risk of Hypoglycemia

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

April 1st 2004

Sources of Error in Drug Interactions: The Swiss Cheese Model

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

March 1st 2004

Computerized Drug-Interaction Alerts: Is Anybody Paying Attention?

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

February 1st 2004

Trending on Pharmacy Times

ADA 2026: Why Some T2D Patients Don't Respond to GLP-1 RAs—And What Pharmacists Should Screen For

ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

New Research Suggests Bempedoic Acid Outperforms Ezetimibe for Heart Health in Patients with Type 2 Diabetes

ADA 2026: Pharmacist CE Programs May Reduce Clinical Inertia in Type 2 Diabetes